GLP-1RAs have diverse effects, including alleviating neuroinflammation and pain in OA, reducing food intake and improving body weight, protecting peripheral nerves, maintaining astrocyte function and metabolic homeostasis, and showing potential therapeutic benefits in AD and PD
registration ID: CRD420251002785)
Managing common side effects Like other weight loss medications, tirzepatide can also cause mild to moderate gastrointestinal side effects such as nausea (most common), diarrhea, and constipation, especially during the start of treatment or when the dose is increased
Additionally, patients on dual therapy would face doubled medication costs, doubled adherence burden, and no clinical evidence of superior outcomesmaking the risk-benefit calculation clearly unfavorable compared to optimizing a single agent